



Tetraphase Pharmaceuticals  
Investor Relations Department  
480 Arsenal Street, Suite 110  
Watertown, MA 02472  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: TTPH

Last Trade:	5.73
Trade Time:	1:41 PM ET Aug 17, 2017
Change:	-0.05 <span style="color: red;">↓</span> (-0.865%)
Day Range	5.73 - 5.99
52-Week Range	3.11 - 9.93
Volume	432,970


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Since the company's inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

... [\(more\)](#)

## Stock Information



### Press Releases [\[ View all \]](#)

- Aug 17, 2017**  
[Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency](#)
- Aug 2, 2017**  
[Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Achievements](#)
- Jul 27, 2017**  
[Tetraphase Announces Pricing of Public Offering of Common Stock](#)
- Jul 26, 2017**  
[Tetraphase Announces Proposed Public Offering of Common Stock](#)
- Jul 25, 2017**  
[Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections](#)

### Financials & Filings [\[ View all \]](#)

- Mar 13, 2017**  
[Annual Report \(10-K\)](#)
- Apr 21, 2017**  
[Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017**  
[Quarterly Report \(10-Q\)](#)
- May 8, 2017**  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016**  
[Quarterly Report \(10-Q\)](#)